6.34
0.94%
-0.06
After Hours:
6.34
CollPlant Biotechnologies Ltd stock is currently priced at $6.34, with a 24-hour trading volume of 3,178.
It has seen a -0.94% decreased in the last 24 hours and a +20.99% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.23 pivot point. If it approaches the $6.57 resistance level, significant changes may occur.
Previous Close:
$6.40
Open:
$6.39
24h Volume:
3,178
Market Cap:
$72.62M
Revenue:
$10.96M
Net Income/Loss:
$-7.02M
P/E Ratio:
-10.06
EPS:
-0.63
Net Cash Flow:
$-3.72M
1W Performance:
-4.35%
1M Performance:
+20.99%
6M Performance:
+21.92%
1Y Performance:
-7.89%
CollPlant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
CollPlant Biotechnologies Ltd
Sector
Industry
Phone
972 73 232 5600
Address
3 Sapir Street, Weizmann Sciences Park, Ness Ziona
CollPlant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-17-23 | Initiated | Alliance Global Partners | Buy |
CollPlant Biotechnologies Ltd Stock (CLGN) Latest News
3D Bioprinting Market Worth $2.4 billion | MarketsandMarkets™ - PR Newswire
PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND ... - PR Newswire
PR Newswire
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Drop in Short Interest - MarketBeat
MarketBeat
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock? - Yahoo Canada Finance
Yahoo Canada Finance
CollPlant Biotechnologies (NASDAQ:CLGN) Shares Down 1.2% - MarketBeat
MarketBeat
CollPlant Biotechnologies (NASDAQ:CLGN) adds US$7.9m to market cap in the past 7 days, though investors from three years ago are still down 60% - Simply Wall St
Simply Wall St
CollPlant Biotechnologies Ltd Stock (CLGN) Financials Data
CollPlant Biotechnologies Ltd (CLGN) Revenue 2024
CLGN reported a revenue (TTM) of $10.96 million for the quarter ending December 31, 2023, a +3,565% rise year-over-year.
CollPlant Biotechnologies Ltd (CLGN) Net Income 2024
CLGN net income (TTM) was -$7.02 million for the quarter ending December 31, 2023, a +58.53% increase year-over-year.
CollPlant Biotechnologies Ltd (CLGN) Cash Flow 2024
CLGN recorded a free cash flow (TTM) of -$3.72 million for the quarter ending December 31, 2023, a +75.24% increase year-over-year.
CollPlant Biotechnologies Ltd (CLGN) Earnings per Share 2024
CLGN earnings per share (TTM) was -$0.64 for the quarter ending December 31, 2023, a +58.44% growth year-over-year.
About CollPlant Biotechnologies Ltd
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. has a license, development, and commercialization agreement with United Therapeutics Corporation for 3D bioprinting of solid-organ scaffolds for human transplants. The company is headquartered in Ness Ziona, Israel.
Cap:
|
Volume (24h):